Tvardi Therapeutics, Inc. (TVRD)
- Previous Close
28.34 - Open
30.21 - Bid 28.74 x 100
- Ask 30.78 x 100
- Day's Range
28.50 - 31.22 - 52 Week Range
8.14 - 34.31 - Volume
67,740 - Avg. Volume
26,123 - Market Cap (intraday)
278.534M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.25 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.75
Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.
tvarditherapeutics.comRecent News: TVRD
View MorePerformance Overview: TVRD
Trailing total returns as of 6/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TVRD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TVRD
View MoreValuation Measures
Market Cap
278.53M
Enterprise Value
269.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-2.25
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--